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OBJECTIVES The goal of this study was to compare the effects of the vasopeptidase inhibitor omapatrilat
and the angiotensin-converting enzyme inhibitor (ACEI) captopril in the postmyocardial
infarction (MI) rat model.
BACKGROUND The cardioprotective effects of ACEIs after MI are thought to be partially due to an increase
in bradykinin (BK). Vasopeptidase inhibitors inhibit both ACE and neutral endopeptidase
(NEP), further reduce BK metabolism and increase natriuretic peptides, which may result in
better cardioprotective effects than with ACEIs after MI.
METHODS Myocardial infarction was induced in 514 Wistar male rats by ligation of the anterior coronary
artery. Rats surviving 4 h after MI (n  282) were assigned to omapatrilat (40 or
80 mg/kg/day), captopril (160 mg/kg/day) or no treatment. After 56 days, neurohumoral,
hemodynamic, ventricular remodeling, morphometry, immunohistochemistry and cardiac
cytokine expression were measured.
RESULTS Omapatrilat and captopril resulted in similarly improved survival, cardiac hemodynamics and
reduced cardiac fibrosis and hypertrophy after MI. The pattern of left ventricular (LV)
remodeling differed, omapatrilat causing less attenuation of the rightward shift of the LV
pressure-volume relation at lower filling pressures than captopril. Both interventions
reduced messenger ribonucleic acid expression of the profibrotic cytokine transforming
growth factor-1; neither effected the anti-inflammatory cytokine interleukin-10, and
only captopril reduced the proinflammatory cytokine tumor necrosis factor-alpha (TNF-
). Expression of TNF- was in cardiomyocytes. Both medications reduced circulating
endothelin-1, angiotensin II and catecholamines, but only omapatrilat increased atrial
natriuretic peptides.
CONCLUSIONS This study indicates that both omapatrilat and captopril markedly improve post-MI
survival, cardiac function and cardiac remodeling in the rat. It would appear that the
addition of NEP inhibition to those of ACEIs does not result in significant further
benefit after MI. (J Am Coll Cardiol 2002;39:1692– 8) © 2002 by the American
College of Cardiology Foundation
Angiotensin-converting enzyme inhibitors (ACEIs) have
been shown to reduce cardiac remodeling and to prolong
survival after myocardial infarction (MI) in experimental
models and in patients (1). Although we initially thought
that ACEIs exerted their beneficial effects exclusively by
reducing the synthesis of angiotensin II (Ang II), there is
now mounting evidence that they exert at least some of their
beneficial effects by inhibiting the degradation of the en-
dogenous vasodilator bradykinin (BK) as well (2).
A new class of medications that inhibit both the ACE
and neutral endopeptidase (NEP) enzymes, called vasopep-
tidase inhibitors (VPI), further enhance nitric oxide and
vasodilator prostaglandins and increase other endogenous
vasodilators, such as natriuretic peptides and adrenomedul-
lin, by blocking their metabolism (3). A recent study
demonstrating beneficial effects of a 62-h infusion of atrial
natriuretic peptide (ANP) in patients with an acute anterior
MI would suggest that further enhancement of this endog-
enous vasodilator system is useful after MI (4). The VPI
omapatrilat has a balanced effect on both the NEP and the
ACE enzymes, with an inhibition constant in the nanomo-
lar range for both enzymes (5). In the cardiomyopathic
hamster, it has been shown to prolong survival more than
the ACEI captopril (6), and, in the pacing overdrive dog
model of heart failure, it has been shown to preserve
myocardial contractility (7). In one clinical study of patients
with heart failure, omapatrilat compared favorably with the
ACEI lisinopril (5).
In this study, we compared the effects of the VPI
omapatrilat on post-MI survival, ventricular function, remod-
eling and neurohumoral activation to those of the ACEI
captopril. Because VPIs may also enhance systemic and local
inflammatory responses by further increasing BK levels (8), we
also measured cardiac messenger ribonucleic acid (mRNA)
expression of several cytokines. Our hypothesis was that
omapatrilat would exert greater beneficial effects on survival,
ventricular function and remodeling than the ACEI captopril.
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METHODS
MI. Myocardial infarction was induced in 514 male Wistar
rats (Charles River, St-Constant, Quebec, Canada) weigh-
ing 200 g to 250 g through ligation of the left anterior
descending coronary artery as previously described (9). All
of the animal experiments followed the guidelines of the
Canadian Council on Animal Care and were approved by
the Animal Care Ethics Committee of the Montreal Heart
Institute (Montreal, Quebec, Canada). The sham ligation
group underwent a similar procedure except that the suture
was not tightened around the coronary artery.
Drug randomization. The ACEI captopril and the VPI
omapatrilat, which acts by combined inhibition of ACE
(inhibitory concentration of 50% activity [IC50]  5 nM)
and NEP (IC50  9 nM), were provided for research
purposes by Bristol-Myers Squibb (Princeton, New Jersey).
Rats were randomly divided into four groups (Fig. 1). An
intraperitoneal injection of the different medications were
administered 4 h after MI and the morning after MI. A first
group received subcutaneous injections of saline followed by
normal food (untreated group, n  99). A second group
received an intraperitoneal injection of omapatrilat 4 mg/kg
and 40 mg/kg/day in food thereafter (n  62) (7). A third
group received an intraperitoneal injection of omapatrilat
8 mg/kg and 80 mg/kg/day in food thereafter (n  56) (5).
A fourth group received an intraperitoneal injection of capto-
pril 16 mg/kg and 160 mg/kg/day in food thereafter (n 65).
Cardiac hemodynamic measurements. After 56 days of
therapy, the rats were anesthetized with an intramuscular
injection of ketamine (50 mg/kg) (Rogar/STB Montreal,
Quebec, Canada) and xylazine (10 mg/kg) (Bayer Canada,
Etobicoke, Ontario, Canada) mixture. An electrocardio-
gram was performed, and the left (LV) and right ventricular
(RV) pressures were measured by a Millar Micro-Tip
Catheter Transducer (Millar Instruments, Houston, Texas)
as previously described (9).
Serum neurohumoral measurements. After the hemody-
namic measurements were obtained, a catheter was intro-
duced in the right jugular vein for blood sampling. Serum
ANP, Ang II, endothelin-1 (ET-1) and catecholamines
were measured by methods described previously (9).
Ventricular remodeling group. PASSIVE PRESSURE-
VOLUME RELATION. After completing the cardiac hemody-
namic measurements, 144 rats had their hearts stopped in
Abbreviations and Acronyms
ACEI  angiotensin-converting enzyme inhibitor
Ang II  angiotensin II
ANP  atrial natriuretic peptide
AW  atrial weight
BK  bradykinin
BW  body weight
ET-1  endothelin-1
IgG  immunoglobulin-G
IL  interleukin
LV  left ventricle/ventricular
LVEDP  left ventricular end-diastolic pressure
LVSP  left ventricular systolic pressure
LVW  left ventricular weight
MI  myocardial infarction
mRNA  messenger ribonucleic acid
NEP  neutral endopeptidase inhibitor
RT-PCR  reverse transcriptase-polymerase chain
reaction
RV  right ventricle/ventricular
RVSP  right ventricular systolic pressure
RVW  right ventricular weight
TGF-  transforming growth factor-beta
TNF-  tumor necrosis factor-alpha
VPI  vasopeptidase inhibitor
dP/dt  maximum rate of pressure rise
Figure 1. Flow diagram of various groups of rats according to the presence of myocardial infarction (MI) and treatment group. All rats were randomized
4 h after coronary artery ligation. The MI size was determined at the end of the study, and, thereafter, the rats were classified according to their MI size.
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diastole, and three pressure-volume curves were obtained
within 10 min; an average of these three curves was used as
the final value, as previously described (9).
Morphologic characteristics of mid-LV cross-sections.
Once the pressure-volume curve was completed, the LV was
filled with saline solution to a pressure of 15 mm Hg, sealed
and fixed in its distended form in 10% formalin phosphate
buffer for 24 h. Right and left atria and both RV and LV
weights were determined. Two cross-sections were obtained
at 1-mm intervals midway between the base and the apex of
the LV. Transverse sections of 4-m thick were cut, and
two cross-sections of each LV were used to assess cardiac
characteristics by planimetry, as previously described (9).
Rats with a moderate-to-large MI were defined as those
having an infarct size 30% of the myocardium. Those
having an LV infarct size 25% were defined as those
having a sham-to-small MI. Those having an LV infarct
size between 25% and 30% were excluded.
Assessment of cardiac fibrosis. This procedure consisted
of using samples from both cross-sections cut into 8-m
thick slices and stained with Sirius red F3BA. The collagen
network was quantified by computer-assisted image analy-
sis; collagen volume density fraction was determined as
previously described (9) by measuring the area of stained
tissue within a given field and expressing that area as a
proportion of the total area under observation. The
collagen-rich border zone of vessels was not included in the
calculations. Ten fields were analyzed in the subendocardial
layer and ten fields in the subepicardial layer in each LV.
Immunohistochemistry for tumor necrosis factor-alpha
(TNF-). Expression of TNF- in cardiac tissues was
determined on two of the cardiac cross-sections (6 m).
Sections were exposed to goat polyclonal anti-rat TNF-
immunoglobulin-G (IgG) (1:100 dilution) (R&D Systems,
Minneapolis, Minnesota). A purified nonspecific goat IgG
(1:100 dilution) was used as a primary negative control. The
secondary antibodies were biotinylated horse anti-goat IgG
(1:400 dilution) (Santa Cruz, Santa Cruz Biotechnology
Inc., California). Revelation of bound antibodies was
achieved with an avidin/peroxidase complex (Vector Labo-
ratories Inc., Burlingame, California) and counter-stained
in Gill’s hemotoxylin solution. Positive TNF- expression
was confirmed by a specific brown staining of the cells. Each
segment was analyzed with a dedicated 3CCD video mi-
croscope adapted to a customized software by an unbiased
observer.
Morphology and cytokine mRNA expression group.
MORPHOLOGIC PARAMETERS OF HEARTS AT TIME OF IN-
DUCED DEATH. After completing the cardiac hemodynamic
measurements, a total of 138 rats were used for biochemical
and molecular biologic measurements. All portions of the
hearts, as well as the lungs and the kidney, were then
weighed individually, frozen in liquid nitrogen and stored at
80°C until used for biochemical investigations. The
scarred area was pinned on a paper, and its surface was
determined by planimetry (Labtronics Inc., Guelph, On-
tario, Canada). Rats with a moderate-to-large MI were
defined as those having an LV scar of 0.8 cm2 of the
surface of the scar (9). Those with an LV scar of 0.5 cm2
were defined as those having a sham-to-small. Those with
an LV scar between 0.5 cm2 and 0.8 cm2 MI were excluded.
Reverse transcriptase-polymerase chain reaction (RT-
PCR) analysis of TNF-, transforming growth factor-
beta (TGF-1) and interleukin-10 (IL-10) mRNA ex-
pression. The RT-PCR experiments were performed on
total ribonucleic acid based on a method published by
Dukas et al. (10). The following oligonucleotides were
utilized as PCR primers: 5-T ACT GAA CTT CGG
GGT GAT TGG TCC-3; and 5-CAG CCT TGT
CCC TTG AAG AGA ACC-3; (Clontech, Palo Alto,
California) were used as sense and anti-sense primers,
respectively, for the amplification of a specific rat TNF-
fragments; 5-C TTC AGC TCC ACA GAG AAG AAC
TGC-3 and 5-CAC GAT CAT GTT GGA CAA CTG
CTC C-3 (Clontech) were used as sense and anti-sense
primers, respectively, for the amplification of the specific rat
TGF-1 fragment, and 5-TG AAG GTC GGT GTC
AAC GGA TTT GGC-3 and 5-CAT GTA GGC CAT
GAG GTC CAC CAC-3 (Clontech) were used as sense
and anti-sense primers, respectively, for the amplification of
the specific rat glyceradlehyde-3-phosphate dehydrogenase
fragment. The oligonucleotides utilized as PCR primers for
IL-10 were purchased from BioSource International (Cam-
arillo, California) and used according to the conditions
established by the manufacturer.
Statistical analysis. All data are expressed as means 
SEM. Statistical significance was calculated using a one-way
analysis of variance and, when indicated, a post-hoc Bon-
ferroni’s test for multiple comparisons. The significance of
any differences between two groups was tested using a
Student’s unpaired t test when appropriated. Only proba-
bility values of p 0.05 were accepted as statistically
significant. Kaplan-Meier survival curves over the follow-up
period were constructed and analyzed by the generalized
savage (Mantel-Cox) test.
RESULTS
Survival. Rats in the sham-to-small MI groups all survived
until the end of the study (Fig. 1). In the untreated rats,
there were 52 sham-to-small MI, and 47 with a moderate-
to-large MI, of which 15 died and 32 survived (68%
survival). Of the rats receiving omapatrilat 40 mg/kg/day,
27 were sham-to-small MI, and 35 had a moderate-to-large
MI, of which 4 died and 31 survived (89% survival, p 0.01
vs. untreated). Of the rats receiving omapatrilat 80 mg/kg/
day, 23 were sham-to-small MI, and 33 had a moderate-
to-large MI, of which 5 died and 28 survived (85% survival,
p  0.06 vs. untreated). Of the rats receiving captopril, 29
were sham-to-small MI, and 36 had a moderate-to-large
MI, of which 4 died and 32 survived (89% survival, p 0.03
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vs. untreated). In moderate-to-large MI, a mean of 40% to
44% of the LV circumference was infarcted.
Hemodynamic measurements. In sham-to-small MI rats,
the various treatment regimens resulted in a decrease in LV
systolic pressure (LVSP) and with omapatrilat by a decrease
in the maximum rate of pressure rise of the LV (dP/dt)
(Table 1). No other change in hemodynamic parameters
was observed.
As compared with sham-to-small MI, untreated
moderate-to-large MI rats had a decrease in LVSP and LV
dP/dt and an increase in LV end-diastolic pressure
(LVEDP), in RV systolic pressure (RVSP) and RV dP/
dt. Right ventricular end-diastolic pressure did not change.
All treatments further decreased LVSP and LVEDP,
which, nevertheless, remained higher than in the sham-to-
small MI groups. All treatment groups decrease in RVSP
and RV dP/dt as compared with untreated moderate-to-
large MI, but this did not reach statistical significance in the
80-mg/kg/day omapatrilat group.
Serum neurohumoral measurements. In sham-to-small
MI rats, serum Ang II, ET-1 and catecholamines were
similar, regardless of treatment group; ANP was increased
in the two omapatrilat groups (from 10  0.5 pg/ml in
untreated to 41  3 pg/ml for both omapatrilat, p  0.05).
In the moderate-to-large MI untreated group, all neuro-
humoral levels increased: ANP from 10  0.5 pg/ml to
41  3 pg/ml, p  0.05; Ang II from 53  4 pg/ml to
886  72 pg/ml, p  0.05; ET-1 from 0.7  0.1 to 2.5 
0.5 pg/ml, p 0.05; norepinephrine 54 3 pg/ml to 309
24 pg/ml, p  0.05; epineprine and dopamine (data not
shown). All treatments resulted in a decrease in Ang II
(range of 33 to 59 pg/ml, p 0.05), ET-1 (range of 0.84 to
0.98 pg/ml, p  0.05) and norepinephrine (range of 102 to
152 pg/ml, p  0.05). Captopril (35  2 pg/ml) and
omapatrilat 40 mg/kg (40 1 pg/ml) did not modify ANP,
but omapatrilat 80 mg/kg further increased ANP levels
(98  8 pg/ml, p  0.05 vs. untreated large MI).
Cardiac remodeling and morphologic studies. In sham-
to-small MI rats, the three treatment groups resulted in a
decrease in LV weight (LVW) to body weight (BW) ratio
(2.1  0.3 mg/g to 1.6 to 1.7  0.5 mg/g, p  0.05) and a
decrease in LV circumference and thickness of the intact
tissue as compared with the untreated group (Table 2).
The moderate-to-large MI untreated had an increase in
LVW/BW (2.4  0.5 mg/g, p  0.05) and an even greater
increase in LV dilation (endocardial and epicardial areas).
This was accompanied by an increase in right ventricular
weight (RVW)/BW (0.67  0.05 mg/g, p  0.05), in atrial
weight (AW)/BW (0.54 0.05 mg/g, p 0.05) and in wet
lung weight/BW (3.6  0.07 mg/g to 6.7  0.4 mg/g, p 
Table 1. Hemodynamic Measurements at 56 Days After Infarction
HR
(beats/min)
LVSP
(mm Hg)
LVEDP
(mm Hg)
LV  dP/dt
(mm Hg)
RVSP
(mm Hg)
RVEDP
(mm Hg)
RV  dP/dt
(mm Hg)
Sham-to-small MI
Salin (n  52) 242  5 118  3 6  1 6,595  177 25  0 3  0 1,292  39
Omapatrilat 80 mg/kg (n  23) 248  5 88  2* 7  1 5,294  193* 25  1 3  0 1,212  46
Omapatrilat 40 mg/kg (n  27) 241  5 100  4* 7  1 5,916  183* 24  1 2  0 1,264  34
Captopril 160 mg/kg (n  29) 254  6 99  3* 6  1 6,078  164 27  1 3  0 1,283  64
Moderate-to-large MI
Salin (n  29) 254  7 109  3† 20  2† 5,128  213† 41  3† 3  1 1,762  101†
Omapatrilat 80 mg/kg (n  28) 245  5 86  2* 14  2*† 4,313  213*† 32  3† 4  1 1,514  106†
Omapatrilat 40 mg/kg (n  31) 252  7 92  3*† 13  2*† 4,505  164*† 28  1*† 3  1 1,383  67*
Captopril 160 mg/kg (n  32) 256  7 95  3*† 14  2*† 4,855  233† 29  2* 3  1 1,400  72*
Values are given as mean  SEM. *p  0.05 vs. untreated; †p  0.05 vs. sham-to-small MI.
HR  heart rate; LV  dP/dt  left ventricular rate of pressure development; LVEDP  left ventricular end-diastolic pressure; LVSP  left ventricular systolic pressure;
MI  myocardial infarction; RV  dP/dt  right ventricular rate of pressure development; RVEDP  right ventricular end-diastolic pressure; RVSP  right ventricular systolic
pressure.
Table 2. Morphologic Characteristics of Mild LV Cross-Sections
Infarct Size
(%)
Mean Scar
Thickness
(m)
Epicardial
Myocardium
Length (mm)
Area
Endocardial
(mm2)
Area
Epicardial
(mm2)
Cardiac
Fibrosis
(%)
Sham-to-small MI
Salin (n  31) 10.52  0.17 0.28  0.00 33.09  0.01 5.34  0.00 9.62  0.00 5  0.00
Omapatrilat 80 mg/kg (n  7) 10.68  1.03 0.27  0.00 29.27  0.01* 5.15  0.01 8.23  0.01* 5.5  0.00
Omapatrilat 40 mg/kg (n  19) 7.78  0.25 0.28  0.00 29.81  0.01* 4.65  0.00 7.36  0.00* 3.7  0.00
Captopril 160 mg/kg (n  15) 10.34  0.36 0.25  0.00 29.53  0.01* 5.01  0.00 8.25  0.01* 3.9  0.00
Moderate-to-large MI
Salin (n  17) 0.39  0.36 0.40  0.00† 25.75  0.02† 7.56  0.00† 11.58  0.01† 11.6  0.01†
Omapatrilat 80 mg/kg (n  14) 4.15  0.60 0.52  0.008*† 21.76  0.01*† 6.06  0.00*† 9.04  0.01* 8.3  0.00*†
Omapatrilat 40 mg/kg (n  21) 0.61  0.40 0.53  0.00*† 22.05  0.01*† 5.70  0.00*† 8.44  0.01*† 6.6  0.00*
Captopril 160 mg/kg (n  20) 2.87  0.32 0.44  0.00† 21.54  0.01*† 5.77  0.01*† 8.69  0.01* 5.8  0.00*
Values are given as mean  SEM. *p  0.05 vs. untreated; †p  0.05 vs. sham-to-small MI.
LV  left ventricular; MI  myocardial infarction.
1695JACC Vol. 39, No. 10, 2002 Lapointe et al.
May 15, 2002:1692–8 ACE and NEP Inhibition After Infarction
0.05), compatible with lung congestion. All treatments
resulted in a decrease in LVW/BW (range of 1.9 to 2.0 
0.05 mg/g, p  0.05) and LV dilation despite similar MI
sizes (40% to 44%). This was accompanied by a decrease in
RVW (range of 0.40 mg/g to 0.46  0.02 mg/g, p  0.05),
in AW/BW (range of 0.22 to 0.29  0.02 mg/g, p  0.05)
and in lung/BW (range of 4.2 to 4.8 mg/g  0.3 mg/g, p 
0.05). However, only RVW/BW and AW/BW returned to
sham-to-small MI values. All treatments reduced cardiac
fibrosis similarly in moderate-to-large MI hearts. Omapat-
rilat increased scar thickness more than captopril.
Passive pressure-volume relationships. In sham-to-small
MI rats, pressure-volume relationships were similar regard-
less of treatment group (Fig. 2). As expected, a moderate-
to-large MI caused a rightward shift of this relationship as
compared with sham-to-small MI. At higher filling pres-
sures (15, 20, 30 mm Hg), all treatments improved this
relationship by causing a leftward shift, but not to normal
values. However, at lower filling pressures (0, 2.5, 5 and
10 mm Hg), omapatrilat caused less of a leftward shift than
captopril, and omapatrilat 80 mg/kg caused a significant
rightward shift in the LV pressure-volume curve as com-
pared with captopril, indicating greater ventricular dilation
at lower filling pressures despite a similar MI size.
Cytokine expression of the LV. As compared with sham-
to-small MI, 56 days after MI the untreated moderate-to-
large MI group had no increase in expression of mRNA for
the inflammatory cytokine TNF-, or for the anti-
inflammatory cytokine IL-10, but had a significant increase
in the hypertrophic and profibrotic cytokine TGF-1 (Fig.
3). Nevertheless, on immunohistochemical staining,
TNF- could be found in the peri-infarct area indicating
localized increased expression. Treatment with omapatrilat
40 mg/kg did not modify TNF- or IL-10 mRNA expres-
sion as compared with untreated moderate-to-large MI but
normalized TGF-1 expression. Captopril also reduced
TGF-1 and did not modify IL-10 expression, but contrary
to omapatrilat, it also reduced TNF- expression to levels
lower than untreated sham-to-small MI and moderate-to-
large MI groups.
DISCUSSION
This study indicates that both the ACEI, captopril and the
VPI omapatrilat markedly improve post-MI survival, car-
diac function and cardiac remodeling in the rat. Despite
causing similar reductions in ventricular weights and cardiac
fibrosis, the pattern of ventricular remodeling differs be-
tween omapatrilat and captopril, the leftward shift in the
LV pressure-volume relationship with omapatrilat being
less marked than with captopril at lower filling pressures.
Both captopril and omapatrilat reduced circulating Ang II,
ET-1 and catecholamines, but only omapatrilat modified
ANP, increasing it. Both interventions reduced mRNA
expression of TGF-1; neither effected mRNA expression
of IL-10, and only captopril reduced TNF-. Thus, despite
some differences in neurohumoral modulation, ventricular
remodeling and effects on cardiac cytokine expression, both
Figure 2. Left ventricle pressure-volume relations according to myocardial infarction (MI) size and treatment group. BMI  large MI.
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captopril and omapatrilat had similar effects on cardiac
function and survival.
Effects on neurohormones. The doses of omapatrilat cho-
sen increased circulating ANP, and, in previous studies,
have been shown to inhibit the pressor response to Ang II
and to increase urinary excretion of ANP in the cardiomyo-
pathic hamster (6) and pacing overdrive dog (7) and to
reduce metabolism of exogenous bradykinin more than
either ACE or NEP inhibition alone (8). In this study, both
captopril and omapatrilat significantly reduced circulating
Ang II in MI rats, consistent with inhibition of ACE
and/or hemodynamic improvement. Also, consistent with
hemodynamic improvement, all groups decreased ET-1 and
norepinephrine. These findings suggest that, in this setting,
concerns regarding deleterious effects of NEP inhibition on
ET-1 and of BK on catecholamine release did not materi-
alize (11). However, these results need to be viewed with
some caution, as circulating neurohumoral values are only
imperfect reflections of what happens at the tissue level.
Effects on survival. Both captopril and omapatrilat re-
sulted in a significant improvement in survival. This oc-
curred despite differences in neurohumoral modulation, in
ventricular remodeling, and cardiac cytokine expression.
This suggests that the common beneficial effects that they
exert on neurohumoral modulation, on cardiac hemody-
namics, on ventricular remodeling and on cardiac cytokine
expression are more important than the differences or that
the differences between the two drugs balance themselves
off. Due to the relatively short follow-up period of the study,
we cannot, however, rule out that one of these differences
would eventually result in improved survival.
Hemodynamic effects. Both captopril and omapatrilat im-
proved cardiac hemodynamics similarly. This was true for
both the LV and RV and at both doses of omapatrilat used.
In addition, both medications decreased lung to BW ratio,
suggesting that both agents also reduced pulmonary con-
gestion. Taken together with the survival data, these find-
ings suggest that omapatrilat does not exert a superior effect
to that of the ACEI captopril. Considering the cardiopro-
tective effects demonstrated for bradykinin in experimental
studies (1,2) and the beneficial effects of an ANP infusion in
patients with an acute anterior MI (4), these results were
somewhat surprising. They suggest that increases in BK
above those caused by ACEIs are not useful and that the
levels of ANP achieved by VPIs after MI are inadequate to
have significant effects in this setting in the rat.
Effects on cardiac remodeling. Both captopril and oma-
patrilat reduced LVW and ventricular dimensions similarly
in the sham-to-small MI groups and in the moderate-to-
large MI groups. Consistent with their hemodynamic ef-
fects, both drugs also reduced RVW, AW and lung weight
in the moderate-to-large MI groups. Interestingly, despite
reducing cardiac fibrosis, omapatrilat resulted in an increase
in scar thickness that appeared to be superior to that of
captopril. The reason for this difference is speculative but
could result from increased peri-MI inflammatory response
in the area of the scar. Increased inflammation could help
prevent early scar expansion by stabilizing the scar, and the
degree of inflammatory response is considered one of the
determinants of scar healing (1). Kinin-B2 receptors have
been found to be upregulated in both the infarcted and
noninfarcted areas of the heart (12) and may be important
for scar stabilization and initiating repair. In a previous
study, we have shown that omapatrilat reduces BK metab-
olism in the scar more than ACEIs (8).
Captopril reduced post-MI ventricular dilation, that is,
change in volume relative to a change in pressure. Although
omapatrilat caused a similar attenuation in this rightward
shift at higher filling pressures, at lower filling pressures (0,
Figure 3. Reverse transcriptase polymerase chain reaction (RT-PCR)
analysis of tumor necrosis factor-alpha (TNF-) (A), transforming growth
factor-beta (TGF-1) (B) and interleukin-10 (IL-10) (C) messenger
ribonucleic acid (mRNA) expression in the left ventricle 56 days after
induction of a moderate-to-large myocardial infarction (MI) or after
sham-to-small operation. Drug treatments (omapatrilat 40 mg/kg/day
[OMA-40] and captopril 160 mg/kg/day [CAP-160]) were started 4 h
after coronary artery ligation. Values are means  SEM of seven to nine
animals in each group. Values (Cytokine-to-glyceraldehyde-3-phosphate
dehydrogenase [GAPDH] ratio, derived from RT-PCR) are arbitrary
scanning units normalized to sham group  1. *p  0.05 vs. sham-to-
small; †p  0.05 vs. MI.
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2.5, 5 and 10 mm Hg) this attenuation was significantly less
than with captopril, particularly in the omapatrilat 80 mg/kg
group. Because the scar in the omapatrilat group was, if
anything, thicker, we are at a loss to explain these findings.
We also cannot explain the equalization of volumes at
higher filling pressures, except to speculate that differences
in the makeup of the fibrotic tissue between captopril and
omapatrilat exist. With omapatrilat 80 mg/kg, the steeper
pressure-volume relationship at higher filling pressures may
have resulted from greater interstitial fibrosis.
Effects on cardiac cytokine mRNA expression. The car-
diac expression of several cytokines were measured because
of a possible omapatrilat-induced BK-induced potentiation
of their expression. In situations of injury, BK is known to
potentiate the inflammatory response (11). Both captopril
and omapatrilat reduced the growth- and fibrosis-
promoting cytokine TGF-1, a finding compatible with the
reduction in LVW and cardiac fibrosis found in hearts
treated with both drugs. Both drugs had no effect on the
expression of the anti-inflammatory IL-10, but only capto-
pril reduced cardiac expression of the proinflammatory
cytokine TNF-. We, as others before us, found that
cardiac expression of TNF- in the noninfarcted area
returned towards baseline levels several weeks after MI, but,
as others before us (13,14), we found that a persistent excess
expression of TNF- occurs in the peri-MI area. By
reducing the expression of TNF-, captopril could prevent
progressive deterioration of LV function after MI and result
in improved long-term survival.
Conclusions. This study indicates that both omapatrilat
and captopril markedly improve post-MI survival, cardiac
function and cardiac remodeling in the rat. It would appear
that the addition of NEP inhibition to ACE inhibition does
not result in significant further benefit.
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